ZOETIS BELGIUM SA

Their core work

Zoetis Belgium is the Belgian subsidiary of Zoetis, the world's largest animal health company (spun off from Pfizer in 2013). In H2020, they contribute pharmaceutical and veterinary expertise to consortia tackling livestock diseases, antimicrobial resistance, and sustainable farming. Their work spans vaccine development for animal parasites and emerging diseases, feed additives to reduce antibiotic use, and digital agriculture platforms. They bring industry-scale knowledge of animal health product development, regulatory pathways, and commercial viability assessment to research partnerships.

What they specialise in

How they've shifted over time

Early H2020 participation (2015–2018) centered squarely on traditional pharma strengths: vaccine development for parasites, emerging diseases like African Swine Fever and Lumpy Skin Disease, and vaccine manufacturing quality control. From 2018 onward, their focus broadened significantly toward non-pharmaceutical solutions — biosecurity measures, non-medicated feed additives, antimicrobial resistance reduction, and digital agriculture through IoT and data platforms. This shift mirrors the wider industry move from treating animal disease to preventing it through integrated farm management.

Zoetis Belgium is moving beyond pharmaceutical products toward data-driven, prevention-first approaches to animal health — expect future interest in precision livestock farming and digital health monitoring.

How they like to work

Zoetis Belgium operates exclusively as a participant, never coordinating — consistent with a large industry player contributing domain expertise and commercial validation to research-led consortia. With 167 unique partners across 37 countries, they engage in large, diverse consortia rather than small focused teams. This makes them an accessible partner: they are experienced in multi-partner EU project dynamics and bring industry perspective without seeking to dominate project direction.

Extensive network of 167 unique partners spanning 37 countries, reflecting participation in large-scale European consortia. Their reach is pan-European with no visible geographic concentration, making them well-connected across the continent's agricultural and veterinary research landscape.

What sets them apart

As the Belgian arm of the world's largest pure-play animal health company, Zoetis brings unmatched commercial and regulatory insight to EU research consortia — they know what it takes to get a veterinary product to market. Their portfolio spans vaccines, feed additives, and digital agriculture, giving them a rare ability to bridge pharmaceutical R&D with on-farm implementation. For consortium builders, Zoetis adds immediate industry credibility and a realistic path to market exploitation of project results.

Highlights from their portfolio

• DEMETER
  Largest EC contribution (EUR 111K) and a strategic pivot into IoT and data-driven agriculture, signaling Zoetis's expansion beyond pharmaceuticals.
• HealthyLivestock
  Highest single funding (EUR 176K) and directly addresses the EU priority of reducing antimicrobial resistance in livestock through biosecurity and welfare improvements.
• DEFEND
  Tackles two high-profile emerging diseases (African Swine Fever and Lumpy Skin Disease) threatening European livestock — a politically and economically urgent topic.